Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Toshiyuki Takemori und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Registries, Sarcoma, Clear Cell. Die Arbeit nennt 17 Literaturangaben. Gefördert von: National Cancer Center Research and Development Funds.
Abstract (Originalsprache)
Background
Clear cell sarcoma is rare, so no reports have previously characterized its national profiles. We examined the nationwide epidemiology and clinical outcomes of patients with clear cell sarcoma based on the National Cancer Registry in Japan.
Methods
Overall, 23 522 patients with soft tissue sarcoma—entered in the National Cancer Registry in 2016–2019 using the International Classification of Diseases for Oncology, Third Edition cancer topography and morphology codes—were enrolled in either the clear cell or the non-clear cell sarcoma group. Data extracted included: demographics (sex and age), tumor details (reason for diagnosis, tumor location, histology and stage), hospital volume and facility type, treatment and prognosis for each patient.
Results
Of 23 522 soft tissue sarcoma patients, 122 were enrolled in the clear cell sarcoma group and 23 400 in the non-clear cell sarcoma group. The incidence of clear cell sarcoma was 0.52% of all soft tissue sarcoma, with an age-adjusted incidence of 0.024/100 000/year. The age at diagnosis was significantly younger, and more tumors were at the localized stage in the clear cell than the non-clear cell sarcoma group. In addition, the overall survival in the clear cell group was worse than in the non-clear cell group (P < 0.001). Of 122 patients with clear cell sarcoma, the localized stage, surgical treatment and treatment without chemotherapy were associated with better overall survival in the univariate analyses.
Conclusions
The present study is the first to have clarified the epidemiology, clinical features, treatment, prognosis and significant factors affecting the prognosis of patients with clear cell sarcoma in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan.
- Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
ORCID-Profile: Toshiyuki Takemori, Shintaro Iwata, Eisuke Kobayashi
Förderung
- National Cancer Center Research and Development Funds
Zitieren
APA
Takemori, T., Ogura, K., Morizane, C., Satake, T., Iwata, S., Toda, Y., Muramatsu, S., Kondo, H., Kobayashi, E., Higashi, T., & Kawai, A. (2024). Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae112
Vancouver
Takemori T, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, et al. Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae112
BibTeX
@article{Takemori2024,
author = {Takemori, Toshiyuki and Ogura, Koichi and Morizane, Chigusa and Satake, Tomoyuki and Iwata, Shintaro and Toda, Yu and Muramatsu, Shudai and Kondo, Hiroya and Kobayashi, Eisuke and Higashi, Takahiro and Kawai, Akira},
title = {Clear cell sarcoma in Japan: an analysis of the population-based cancer registry in Japan},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae112}
}
EUVIMED